Further, since the introduction and approval of glucagon-like peptide-1 (GLP-1) agonists for the treatment of diabetes and obesity, there is new evidence that these medications can disrupt neurohormonal signals, thereby leading to hunger control, as well as diminished desire for highly palatable foods [11]. This evidence concerns the gene GCG and obesity disorder.